Treatment for Metabolic Syndrome by Panchakarma Therapy (Virechana) and Ayurvedic Medicine

Comparative clinical trial to Evaluate the efficacy of Phalatrikadi Ghanvati with and without Virechana Karma in Metabolic Syndrome - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/01/079134

Enrollment

Registered

2025-01-21

Start date

Unknown

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E889- Metabolic disorder, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Patients of either sex of age group 20 to 60 years. 2. Patient fulfilling more than or equal to 3 out of 5 criteria for MetS (according to NCEP ATP III criteria):- I. Abdominal obesity (waist circumference more than 102 cm (40 inches) in men or 88cm (35 inches) in women. II. Serum triglycerides level more than 150mg/dl. III. Low HDL Cholesterol less than 40mg/dl and less than 50mg/dl for men and women,respectively. IV. Blood pressure more than or equal to 130 mmHg systolic or more than or equal to 85 mmHg diastolic. V. Fasting Plasma Glucose level more than 100mg/dl 3. Patient who are considered fit for virechana procedure for group A. 4. Patients willing to give written consent.

Exclusion criteria

Exclusion criteria: Any patients on treatment for Diabetes mellitus, Dyslipidaemia and Hypertension. 2. Patients who present with blood pressure in the following range. systolic more than or equal to 180 mmHg or diastolic more than or equal to 120 mmHg. 3. Patients having Hba1c more than 7 4. Subject having systemic illness, malignancy, major endocrine disorders will be excluded from this study. 5. Know case of IHD, CAD, CCF or other major cardiovascular problems will not be included for this study. 6. Patients with renal (Sr. creatinine more than 1.8mg/dl) OR hepatic impairment SGOT, SGPT and GGT more than five times than normal value. 7. Patients on anti-retroviral, anti-tubercular and antibiotic medications. 8. Pregnant and lactating women will not be included. 9. Patients requiring emergency treatment. 10. For group A : Patients who are contraindicated for virechana karma- like lower GI bleeding, prolapse of rectum, incontinence of stool will not be included.

Design outcomes

Primary

Measure	Time frame
The proportion of patients showing improvement in parameters of extended lipid profile,blood sugar level, blood pressure, waist circumference and BMI after use of phalatrikadi ghanvati with and without virechana karma.Timepoint: Group A- Baseline,after Virechana karma, Day 15, Day 30, Day 45,Day 60,Day 75 Group B - Baseline,day 15,day 30,day 45,day 60,day 75	—

Secondary

Measure	Time frame
The proportion of patients showing changes in the serum adiponectine after use of phalatrikadi ghanvati with & without virechana karma.Timepoint: Group A & Group B -Baseline,Day 75	—

Countries

India

Contacts

Public ContactRitu

Ayurvedic and Unani Tibbia college and hospital, Karol Bagh, New Delhi -110005

nitjin2005@gmail.com9811765501

Outcome results